Crucell 2008
Combating Infectious Diseases
Annual Report and Form 20–F

• What Corporate Social Responsibility means to us
• What we do
• A CSR dilemma
• Crucell on its mission to combat infectious diseases
• Who we work with
• An example: Warm response to cold chain training
• How we do business
• A partnership with customers illustrated
• Crucell's PER.C6^® technology
• How we see our responsibility
• Crucell works in an environment that requires highly skilled employees
• Innovative safety approach
• Beyond legislation for safety
• Environmental impact
• An example: Combining vaccines for a diversity of benefits
• Energy & water consumption
• Economic aspects of our business

Crucell's PER.C6^® technology: A revolution in biopharmaceutical production

Many of today’s vaccines are produced on animal substrates such as chicken eggs and mouse brains. Inherent problems with these manufacturing processes include limited scalability, lengthy processing times, and relatively low success rates due to the potential safety risks associated with animal-derived products.

Crucell’s PER.C6^® technology provides a state-of-the-art alternative. PER.C6^® human cell lines are ideally suited for the development and industrial-scale manufacturing of a wide range of biopharmaceutical products, including vaccines, antibodies and gene therapies. PER.C6^® cell lines are derived from a single cell taken from a human retina and immortalized using recombinant DNA technology. Because PER.C6® cells grow in suspension to very high densities, they provide an excellent platform for the production of many different types of vaccines (inactivated whole-virus, live-attenuated, live-vector, split and subunit vaccines). PER.C6^® technology also allows efficient production of recombinant proteins, such as live adenovirus vector-based vaccines. For more information about Crucell’s PER.C6^® technology, see page 32 of the 2008 Annual Report.